Replimune Group, Inc. (REPL)
NASDAQ
Market Cap
$534.93M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
729 of 809
Rank in Industry
398 of 445
Largest Insider Buys in Sector
REPL Stock Price History Chart
REPL Stock Performance
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Activity of Replimune Group, Inc.
Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $1.84M worth of Replimune Group, Inc. stock.
On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $17.97M and sold $16.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.
List of Insider Buy and Sell Transactions, Replimune Group, Inc.
| 2024-06-07 | Sale | Xynos Konstantinos | Chief Medical Officer | 15,881 0.0245% | $7.50 | $119,108 | +10.89% | |
| 2024-05-16 | Sale | Coffin Robert | director | 11,464 0.0189% | $6.47 | $74,172 | +0.67% | |
| 2024-05-16 | Sale | Astley-Sparke Philip | Executive Chairman | 37,928 0.0626% | $6.47 | $245,394 | +0.67% | |
| 2024-05-16 | Sale | Love Colin | Chief Operating Officer | 17,615 0.0291% | $6.47 | $113,969 | +0.67% | |
| 2024-05-16 | Sale | Patel Sushil | Chief Executive Officer | 20,194 0.0333% | $6.47 | $130,655 | +0.67% | |
| 2024-05-16 | Sale | Xynos Konstantinos | Chief Medical Officer | 6,367 0.0105% | $6.47 | $41,194 | +0.67% | |
| 2024-05-16 | Sale | Sarchi Christopher | Chief Commercial Officer | 2,218 0.0037% | $6.47 | $14,350 | +0.67% | |
| 2024-05-16 | Sale | Schwendenman Andrew | Chief Accounting Officer | 2,298 0.0038% | $6.47 | $14,868 | +0.67% | |
| 2023-11-16 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,313 0.0131% | $10.92 | $79,858 | -24.60% | |
| 2023-11-16 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,255 0.0094% | $10.92 | $57,385 | -24.60% | |
| 2023-09-12 | Sale | Esposito Pamela | Chief Business Officer | 300 0.0005% | $20.00 | $6,000 | -57.25% | |
| 2023-09-11 | Sale | Esposito Pamela | Chief Business Officer | 5,358 0.0092% | $20.01 | $107,214 | -58.56% | |
| 2023-08-22 | Sale | Esposito Pamela | Chief Business Officer | 18,600 0.0315% | $20.01 | $372,186 | -58.23% | |
| 2023-08-11 | Sale | Esposito Pamela | Chief Business Officer | 1,400 0.0024% | $20.00 | $28,000 | -57.30% | |
| 2023-07-10 | Sale | Esposito Pamela | Chief Business Officer | 20,000 0.035% | $21.58 | $431,541 | -58.38% | |
| 2023-06-13 | Sale | Patel Sushil | Chief Strategy Officer | 5,698 0.0098% | $24.05 | $137,008 | -62.70% | |
| 2023-06-13 | Sale | Lewis Tanya | Chief Dev. Op. Officer | 12,860 0.0221% | $24.06 | $309,395 | -62.70% | |
| 2023-05-16 | Sale | Coffin Robert | President & Chief R&D Officer | 7,861 0.0132% | $18.05 | $141,891 | -39.43% | |
| 2023-05-16 | Sale | Astley-Sparke Philip | Chief Executive Officer | 17,902 0.03% | $18.05 | $323,131 | -39.43% | |
| 2023-05-16 | Sale | Love Colin | Chief Operating Officer | 10,775 0.0181% | $18.05 | $194,489 | -39.43% |
Insider Historical Profitability
12.92%
| Coffin Robert | President & Chief R&D Officer | 1821872 2.9865% | $8.71 | 0 | 15 | |
| Astley-Sparke Philip | Chief Executive Officer | 1487350 2.4847% | $8.71 | 0 | 12 | |
| Love Colin | Chief Operating Officer | 777345 1.295% | $8.71 | 0 | 22 | |
| Esposito Pamela | Chief Business Officer | 263436 0.4291% | $8.71 | 0 | 18 | |
| Patel Sushil | Chief Strategy Officer | 212014 0.2425% | $8.71 | 0 | 4 | |
| Xynos Konstantinos | Chief Medical Officer | 117131 0.1836% | $8.71 | 0 | 4 | |
| Sarchi Christopher | Chief Commercial Officer | 92252 0.1177% | $8.71 | 0 | 2 | |
| Schwendenman Andrew | Chief Accounting Officer | 38238 0.0623% | $8.71 | 0 | 1 | |
| Omega Fund IV, L.P. | 4763380 7.7595% | $8.71 | 2 | 20 | +27.98% | |
| Slootweg Hugo Alexander | 4721449 7.6912% | $8.71 | 1 | 0 | <0.0001% | |
| Forbion Capital Fund III Cooperatief U.A. | 10 percent owner | 4721449 7.6912% | $8.71 | 1 | 0 | <0.0001% |
| Stampacchia Otello | 4673380 7.6129% | $8.71 | 0 | 1 | ||
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2838968 4.6246% | $8.71 | 1 | 0 | <0.0001% |
| Rhodes Jason P | director | 946000 1.541% | $8.71 | 1 | 11 | +63.12% |
| Lewis Tanya | Chief Dev. Op. Officer | 135293 0.2204% | $8.71 | 0 | 3 | |
| Franchi Jean M. | Chief Financial Officer | 128748 0.2097% | $8.71 | 0 | 5 | |
| SLATTERY JOSEPH P | director | 6667 0.0109% | $8.71 | 1 | 1 | <0.0001% |
| Dhingra Kapil | director | 0 0% | $8.71 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Baker Bros Advisors LP | $77.99M | 15.54 | 9.55M | 0% | +$0 | 0.98 | |
| T. Rowe Price | $53.51M | 10.66 | 6.55M | +11.96% | +$5.72M | 0.01 | |
| State Street | $53M | 10.56 | 6.49M | +26.9% | +$11.24M | <0.01 | |
| BlackRock | $37.68M | 7.51 | 4.61M | +1.63% | +$605,160.07 | <0.01 | |
| Redmile Group | $30.47M | 6.07 | 3.73M | -3.5% | -$1.11M | 1.13 | |
| Omega Fund Management Llc | $24.52M | 4.89 | 3M | 0% | +$0 | 18.18 | |
| The Vanguard Group | $22.63M | 4.51 | 2.77M | +1.19% | +$265,974.34 | <0.0001 | |
| Camber Capital Management Lp | $22.47M | 4.48 | 2.75M | +175% | +$14.3M | 0.79 | |
| Morgan Stanley | $21.68M | 4.32 | 2.65M | -40.32% | -$14.65M | <0.01 | |
| Atlas Venture Life Science Advisors Llc | $17.14M | 3.42 | 2.1M | 0% | +$0 | 1.64 | |
| Geode Capital Management | $9.74M | 1.94 | 1.19M | +4.08% | +$381,450.56 | <0.01 | |
| Jefferies Financial Group | $8.17M | 1.63 | 1M | New | +$8.17M | 0.15 | |
| D. E. Shaw & Co. | $8.15M | 1.63 | 997,786 | +310.6% | +$6.17M | 0.01 | |
| Dimensional Fund Advisors | $7.99M | 1.59 | 977,852 | -26.09% | -$2.82M | <0.01 | |
| Deerfield Management | $6.56M | 1.31 | 802,984 | -55.68% | -$8.24M | 0.13 | |
| GHOST TREE CAPITAL LLC | $5.31M | 1.06 | 650,000 | +62.5% | +$2.04M | 1.73 | |
| Rafferty Asset Management Llc | $5.25M | 1.05 | 642,078 | +38.56% | +$1.46M | 0.02 | |
| Citigroup | $4.43M | 0.88 | 542,489 | +196.02% | +$2.93M | <0.01 | |
| Deutsche Bank | $4.27M | 0.85 | 522,046 | +278.9% | +$3.14M | <0.01 | |
| Goldman Sachs | $4.19M | 0.84 | 513,340 | -77.07% | -$14.1M | <0.01 | |
| Emerald Advisers, Inc. | $4.02M | 0.8 | 492,219 | -8.65% | -$380,901.72 | 0.16 | |
| Northern Trust | $3.95M | 0.79 | 483,644 | +0.38% | +$14,787.70 | <0.01 | |
| Millennium Management LLC | $3.77M | 0.75 | 461,862 | +2,973.75% | +$3.65M | <0.01 | |
| Charles Schwab | $3.42M | 0.68 | 418,664 | +4.16% | +$136,618.74 | <0.01 | |
| Bank of America | $3.19M | 0.64 | 390,031 | +76.77% | +$1.38M | <0.0001 | |
| UBS | $3.01M | 0.6 | 367,986 | +66.94% | +$1.21M | <0.01 | |
| Wellington Management Company | $2.53M | 0.5 | 309,779 | +25.61% | +$515,976.47 | <0.0001 | |
| Two Sigma | $2.52M | 0.5 | 308,841 | +170.48% | +$1.59M | <0.01 | |
| Woodline Partners LP | $2.4M | 0.48 | 293,622 | 0% | +$0 | 0.02 | |
| Fidelity Investments | $2.34M | 0.47 | 286,479 | -65.31% | -$4.41M | <0.0001 | |
| ClearBridge Investments | $2.27M | 0.45 | 277,969 | +2.69% | +$59,428.56 | <0.01 | |
| JPMorgan Chase | $2.22M | 0.44 | 272,133 | -10.78% | -$268,711.35 | <0.0001 | |
| Amundi | $1.73M | 0.4 | 248,080 | +42.21% | +$513,215.16 | <0.01 | |
| Td Asset Management Inc | $1.95M | 0.39 | 238,846 | -10.76% | -$235,296.02 | <0.01 | |
| Two Sigma Advisers LP | $1.82M | 0.36 | 222,600 | +9.82% | +$162,583.00 | <0.01 | |
| Qube Research & Technologies | $1.81M | 0.36 | 221,222 | -43.95% | -$1.42M | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $1.74M | 0.35 | 212,653 | +17.85% | +$263,163.87 | <0.01 | |
| Nan Fung Group | $1.67M | 0.33 | 204,939 | +10.93% | +$165,034.04 | 1.82 | |
| ExodusPoint Capital Management, LP | $1.4M | 0.28 | 171,015 | +4.14% | +$55,491.16 | 0.02 | |
| BNY Mellon | $1.33M | 0.27 | 162,755 | -3.45% | -$47,533.05 | <0.0001 | |
| Renaissance Technologies | $1.32M | 0.26 | 161,053 | +375.74% | +$1.04M | <0.01 | |
| Schonfeld Group | $1.29M | 0.26 | 158,291 | +273.38% | +$946,878.15 | 0.01 | |
| Jane Street Capital | $1.29M | 0.26 | 157,818 | -35.19% | -$700,119.95 | <0.01 | |
| The Manufacturers Life Insurance Company | $1.21M | 0.24 | 148,172 | -4.25% | -$53,725.91 | <0.01 | |
| Jacobs Levy Equity Management | $1.09M | 0.22 | 133,195 | New | +$1.09M | 0.01 | |
| EMERALD MUTUAL FUND ADVISERS TRUST | $1.08M | 0.22 | 132,413 | -61.89% | -$1.76M | 0.06 | |
| Nuveen | $955,784.00 | 0.19 | 116,987 | 0% | +$0 | <0.0001 | |
| Acadian Asset Management | $927,000.00 | 0.19 | 113,649 | New | +$927,000.00 | <0.01 | |
| Barclays | $885,000.00 | 0.18 | 108,530 | -62.64% | -$1.48M | <0.0001 | |
| Trexquant Investment LP | $820,546.00 | 0.16 | 100,434 | New | +$820,546.00 | 0.01 |